| Influence of HLA-C expression level on HIV control R Apps, Y Qi, JM Carlson, H Chen, X Gao, R Thomas, Y Yuki, ... Science 340 (6128), 87-91, 2013 | 402 | 2013 |
| HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C R Thomas, R Apps, Y Qi, X Gao, V Male, C O'huigin, G O'Connor, D Ge, ... Nature genetics 41 (12), 1290-1294, 2009 | 332 | 2009 |
| HLA/KIR restraint of HIV: surviving the fittest AA Bashirova, R Thomas, M Carrington Annual review of immunology 29, 295-317, 2011 | 176 | 2011 |
| A novel variant marking HLA-DP expression levels predicts recovery from hepatitis B virus infection R Thomas, CL Thio, R Apps, Y Qi, X Gao, D Marti, JL Stein, KA Soderberg, ... Journal of virology 86 (12), 6979-6985, 2012 | 164 | 2012 |
| HIV-1 vpu mediates HLA-C downregulation R Apps, GQ Del Prete, P Chatterjee, A Lara, ZL Brumme, MA Brockman, ... Cell host & microbe 19 (5), 686-695, 2016 | 148 | 2016 |
| FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial SS Li, PB Gilbert, GD Tomaras, G Kijak, G Ferrari, R Thomas, CW Pyo, ... The Journal of clinical investigation 124 (9), 3879-3890, 2014 | 121 | 2014 |
| Human leukocyte antigen class I and II alleles in non-Hodgkin lymphoma etiology SS Wang, AM Abdou, LM Morton, R Thomas, JR Cerhan, X Gao, ... Blood, The Journal of the American Society of Hematology 115 (23), 4820-4823, 2010 | 102 | 2010 |
| Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial TA Crowell, DJ Colby, S Pinyakorn, C Sacdalan, A Pagliuzza, J Intasan, ... The Lancet HIV 6 (5), e297-e306, 2019 | 86 | 2019 |
| Novel KIR3DL1 alleles and their expression levels on NK cells: convergent evolution of KIR3DL1 phenotype variation? R Thomas, E Yamada, G Alter, MP Martin, AA Bashirova, PJ Norman, ... The Journal of Immunology 180 (10), 6743-6750, 2008 | 84 | 2008 |
| High-throughput multiplex HLA genotyping by next-generation sequencing using multi-locus individual tagging PK Ehrenberg, A Geretz, KM Baldwin, R Apps, VR Polonis, ML Robb, ... BMC genomics 15, 1-8, 2014 | 76 | 2014 |
| Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor V Dussupt, RS Sankhala, GD Gromowski, G Donofrio, RA De La Barrera, ... Nature medicine 26 (2), 228-235, 2020 | 71 | 2020 |
| Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption DJ Colby, M Sarnecki, DH Barouch, S Tipsuk, DJ Stieh, E Kroon, ... Nature Medicine 26 (4), 498-501, 2020 | 61 | 2020 |
| HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition HA Prentice, GD Tomaras, DE Geraghty, R Apps, Y Fong, PK Ehrenberg, ... Science translational medicine 7 (296), 296ra112-296ra112, 2015 | 58 | 2015 |
| Variations in HLA-B cell surface expression, half-life and extracellular antigen receptivity B Yarzabek, AJ Zaitouna, E Olson, GN Silva, J Geng, A Geretz, R Thomas, ... eLife 7, e34961, 2018 | 57 | 2018 |
| Killer cell immunoglobulin–like receptor 3DL1 variation modifies HLA-B* 57 protection against HIV-1 MP Martin, V Naranbhai, PR Shea, Y Qi, V Ramsuran, N Vince, X Gao, ... The Journal of clinical investigation 128 (5), 1903-1912, 2018 | 57 | 2018 |
| Ex vivo functional responses to HLA-G differ between blood and decidual NK cells R Apps, A Sharkey, L Gardner, V Male, P Kennedy, L Masters, L Farrell, ... MHR: Basic science of reproductive medicine 17 (9), 577-586, 2011 | 52 | 2011 |
| HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders H Janes, JT Herbeck, S Tovanabutra, R Thomas, N Frahm, A Duerr, ... Nature medicine 21 (10), 1139, 2015 | 48 | 2015 |
| Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infection GH Kijak, E Sanders-Buell, AL Chenine, MA Eller, N Goonetilleke, ... PLoS pathogens 13 (7), e1006510, 2017 | 47 | 2017 |
| HIV-1-specific IgA monoclonal antibodies from an HIV-1 vaccinee mediate galactosylceramide blocking and phagocytosis S Wills, KK Hwang, P Liu, SM Dennison, MZ Tay, X Shen, J Pollara, ... Journal of virology 92 (7), 10.1128/jvi. 01552-17, 2018 | 46 | 2018 |
| Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccine. SRP Fourati S, Ribeiro SP, Blasco Tavares Pereira Lopes F, Talla A, Lefebvre ... Nature communications, 2019 | 36 | 2019 |
Richard Apps在 mail.nih.gov 的电子邮件经过验证
